Cipla receives final approval for generic version of AstraZeneca Pharmaceutical’s Nexium (Esomeprazole for Oral Suspension 10mg, 20mg and 40mg)
With this, Cipla has become the first company to file for the 10 mg variant strength of the product
Cipla recently announced that it has received final approval for its Abbreviated New Drug Application (ANDA) for Esomeprazole for Oral Suspension 10mg, 20mg and 40mg from the United States Food and Drug Administration (US FDA). Cipla is the first company to file for the 10 mg strength.
Cipla’s Esomeprazole for Oral Suspension 10mg, 20mg and 40mg is AB-rated generic therapeutic equivalent version of AstraZeneca Pharmaceutical’s Nexium. It is a proton pump inhibitor indicated for the following:
- Treatment of gastroesophageal reflux disease (GERD)
- Risk reduction of NSAID-associated gastric ulcer
- H pylori eradication to reduce the risk of duodenal ulcer recurrence
- Pathological hypersecretory conditions, including Zollinger-Ellison syndrome
According to IQVIA (IMS Health), Nexium and its generic equivalents had US sales of approximately $ 70-mn for the 12-month period ending November 2019.
The product is available for shipping immediately.